Amelioration of acylcarnitine profile using bezafibrate and riboflavin in a case of adult-onset glutaric acidemia type 2 with novel mutations of the electron transfer flavoprotein dehydrogenase (ETFDH) gene
Authors:
- 1 November 2014
- journal article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 346 (1-2) , 350-352
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: Evaluation by in vitro probe acylcarnitine assayMolecular Genetics and Metabolism, 2012
- Lipid Storage MyopathyCurrent Neurology and Neuroscience Reports, 2010
- In vitro probe acylcarnitine profiling assay using cultured fibroblasts and electrospray ionization tandem mass spectrometry predicts severity of patients with glutaric aciduria type 2Journal of Chromatography B, 2010
- Long-Term Follow-Up of Bezafibrate Treatment in Patients With the Myopathic Form of Carnitine Palmitoyltransferase 2 DeficiencyClinical Pharmacology & Therapeutics, 2010
- Clinical and molecular investigations of Japanese cases of glutaric acidemia type 2Molecular Genetics and Metabolism, 2008
- Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disordersHuman Molecular Genetics, 2005
- Clear relationship betweenETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiencyHuman Mutation, 2003
- Possible deleterious effect ofL‐carnitine supplementation in a patient with mild multiple acyl‐CoA dehydrogenation deficiency (ethylmalonic‐adipic aciduria)Journal of Inherited Metabolic Disease, 1990
- Systemic carnitine deficiency due to lack of electron transfer flavoproteinNeurology, 1986
- Glutaric aciduria type II: Report on a previously undescribed metabolic disorderClinica Chimica Acta, 1976